Hodgkin Lymphoma
Conference Coverage
PD-1 checkpoint inhibitors show mettle against relapsed Hodgkin’s lymphoma
Key clinical point: PD-1 checkpoint inhibition appears to be an effective strategy against treatment-refractory Hodgkin’s lymphoma. Major finding...
Conference Coverage
Speaker advocates chemo-based salvage in HL
Credit: Rhoda Baer NEW YORK—Physicians should use chemotherapy-based approaches—not brentuximab vedotin—as second-line therapy for recurrent...
Conference Coverage
Brentuximab tops chemo in HL, doc says
NEW YORK—Brentuximab vendotin—not conventional chemotherapy—is the second-line regimen of choice for recurrent Hodgkin lymphoma (HL) patients...
News
Risk factors for premature menopause in HL survivors
Credit: NCI The risk of premature menopause among survivors of Hodgkin lymphoma (HL) may vary greatly, according to a study of more than 2000...
News
Repeat biopsy and long-term surveillance key for rare Hodgkin’s lymphoma subtype
Key clinical point: Repeat biopsy and long-term surveillance are necessary in nodular lymphocyte-predominant Hodgkin’s lymphoma. Major finding:...
News
Screening catches breast cancer early in HL survivors
Results of a new study indicate that MRI and mammography can detect invasive breast tumors at very early stages in female survivors of Hodgkin...
News
Inhibitor gets breakthrough designation for HL
The FDA’s decision is based on data from a cohort of HL patients in an ongoing phase 1b study of patients with relapsed or refractory hematologic...
News
Omitting RT can increase risk of relapse in HL
Credit: Sue Campbell Interim results of a randomized trial suggest that omitting radiotherapy in Hodgkin lymphoma patients with an early negative...
News
Mutations appear to drive lymphoma development
Credit: Rhoda Baer Mutations in the gene PTPN1 may drive the development of Hodgkin lymphoma (HL) and primary mediastinal B-cell lymphoma (PMBCL...
News
Brentuximab vedotin approved in Japan
Credit: Linda Bartlett The Japanese Ministry of Health, Labour and Welfare has approved brentuximab vedotin (Adcetris) for the treatment of...